Literature DB >> 6812816

Graft-versus-host disease.

A M Denman.   

Abstract

Entities:  

Mesh：

Year:  1982        PMID： 6812816      PMCID： PMC1499779          DOI： 10.1136/bmj.285.6350.1226

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  17 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

2.  Decrease in the graft rejection rate and improvement in survival after marrow transplantation for severe aplastic anemia.

Authors:  R Storb
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Marrow transplantation for thalassaemia.

Authors:  E D Thomas; C D Buckner; J E Sanders; T Papayannopoulou; C Borgna-Pignatti; P De Stefano; K M Sullivan; R A Clift; R Storb
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

4.  T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions.

Authors:  W Friedrich; R J O'Reilly; B Koziner; D F Gebhard; R A Good; R L Evans
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

5.  A randomized study of the prevention of acute graft-versus-host disease.

Authors:  N K Ramsay; J H Kersey; L L Robison; P B McGlave; W G Woods; W Krivit; T H Kim; A I Goldman; M E Nesbit
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

6.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.

Authors:  P L Weiden; K M Sullivan; N Flournoy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

7.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

8.  The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation.

Authors:  J Hersman; J D Meyers; E D Thomas; C D Buckner; R Clift
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

9.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

10.  Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial.

Authors:  J C Wade; B Newton; C McLaren; N Flournoy; R E Keeney; J D Meyers
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.